Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2024-05-20 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
北京市万商天勤律师事务所关于重庆博腾制药科技股份有限公司2023年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2023 Annual General Meeting (AGM) of Chongqing Boteng Pharmaceutical Technology Co., Ltd. It details the convening, attendance, voting procedures, and results of the AGM, confirming compliance with relevant laws and company articles. The document is not the AGM materials or presentations themselves but a legal opinion on the AGM process and results. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports on the AGM voting outcomes and procedural legality. The document length is under 5,000 characters, and it is a formal legal opinion rather than the AGM presentation or minutes, so it is not AGM Information (AGM-R).
2024-05-20 Chinese
2023年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度募集资金存放与使用情况专项报告" which translates to "2023 Annual Special Report on the Deposit and Use of Raised Funds." It details the amount of funds raised, their deposit, usage, changes in investment projects, and compliance with regulatory requirements. The document includes detailed tables on the use of raised funds, changes in projects, and management of these funds. It references regulatory guidelines related to the management and use of raised funds and includes disclosures about changes in the use of funds and project progress. This type of report is a specialized disclosure on the use of capital raised by the company, which fits the category of Capital/Financing Update (CAP). It is not a full annual report, audit report, or earnings release, but a focused report on fundraising and capital usage. The document length is sufficient and contains substantive financial data related to capital usage, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2024-04-26 Chinese
关于2024年度开展以套期保值为目的的外汇衍生品交易业务的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding the company's plan to engage in foreign exchange derivative trading for hedging purposes in 2024. It details the investment types, amounts, risk analysis, risk control measures, and approvals by the board and supervisory committee. The document is an announcement of a corporate financing or capital management activity related to hedging foreign exchange risk, but it does not contain financial statements or quarterly/yearly financial results. It is not an annual or interim report, earnings release, or audit report. It is not a regulatory filing or certification. The document is a capital/financing update about the company's planned derivative transactions and risk management strategy. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 3336 characters, which is consistent with an announcement rather than a full report.
2024-04-26 Chinese
董事会审计委员会对会计师事务所2023年度履职情况评估及履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee evaluating the performance of the accounting firm for the year 2023. It discusses the audit firm's qualifications, audit procedures, and the audit committee's supervision of the audit process for the company's 2023 annual financial statements. The document includes details about the audit firm's background, audit scope, and the audit committee's meetings and evaluations related to the 2023 audit. It is not the audit report itself but a supervisory report on the audit firm's performance and the audit process. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory oversight related to audits, excluding the full Annual Report. The document length is under 5,000 characters but contains substantive content about audit oversight, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence.
2024-04-26 Chinese
2023年度董事会工作报告
Management Reports Classification · 95% confidence The document is titled '2023 年度董事会工作报告' which translates to '2023 Annual Board of Directors Work Report'. It contains detailed information about the company's business operations, financial performance, strategic initiatives, ESG efforts, and board activities for the year 2023. It includes comprehensive data such as revenue figures, business segment performance, R&D investments, and future plans. The document also discusses board meetings, committee activities, and changes in board membership. The length of the document (8625 characters) and the depth of content indicate it is a detailed management report rather than a brief announcement or a simple voting result. It is not a full annual report (10-K) as it lacks full financial statements but is a detailed explanation of business trends, operations, and outlook by management. Therefore, it fits best under Management Reports (MDA).
2024-04-26 Chinese
监事会关于公司2023年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board's review opinion on the company's 2023 internal control self-evaluation report. It references relevant laws and regulations and provides an official opinion on the internal control report. The document is very short (463 characters) and does not contain the full internal control report itself, only the supervisory board's verification opinion. This fits the pattern of an Audit Report / Information (AR) type, which includes audit reports and internal control evaluations separate from full annual reports. It is not an announcement or publication notice, nor a certification letter. Therefore, the best classification is AR with high confidence.
2024-04-26 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.